AstraZeneca's IMFINZI-EV Combo Gains FDA Priority Review for Bladder Cancer

  • AstraZeneca's sBLA for IMFINZI plus enfortumab vedotin (EV) in muscle-invasive bladder cancer (MIBC) received FDA Priority Review.
  • The FDA action date under the Prescription Drug User Fee Act (PDUFA) is anticipated in Q4 2026.
  • The application is based on the VOLGA Phase III trial, showing statistically significant improvements in event-free survival (EFS) and overall survival (OS).
  • Approximately 50% of MIBC patients are ineligible for cisplatin-based chemotherapy, creating a significant unmet need.

AstraZeneca's IMFINZI plus EV combination represents a strategic push into the perioperative treatment of muscle-invasive bladder cancer, an area with high unmet need. The FDA's Priority Review designation underscores the potential for this regimen to offer significant improvements over existing treatments, particularly for patients ineligible for cisplatin-based chemotherapy. If approved, this could solidify IMFINZI's role as the immunotherapy backbone in bladder cancer treatment.

Regulatory Success
Whether the FDA will approve IMFINZI plus EV by the PDUFA date in Q4 2026, potentially setting a new standard of care for MIBC.
Market Impact
How this approval could expand AstraZeneca's leadership in bladder cancer treatment and impact competitors in the space.
Clinical Adoption
The pace at which oncologists adopt this perioperative regimen, given its potential to improve outcomes for cisplatin-ineligible patients.